Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,695
- 试验地点
- 115
- 主要终点
- Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean diastolic blood pressure (DBP)
研究概览
简要总结
This study will investigate two registered drugs, one for the treatment of high blood pressure and one for the treatment of elevated cholesterol. High blood pressure (hypertension) is a common medical condition affecting millions of people worldwide. A wide variety of effective drug treatments is available to reduce blood pressure. Elevated cholesterol (hypercholesterolemia) is a common medical condition affecting people worldwide. A wide variety of effective drug treatments is available to reduce cholesterol levels.
Hypertension and hypercholesterolemia often occur together. They are both important risk factors for the development of heart and vessel diseases (e.g. heart attack or stroke). Current guidelines advise treatment of high blood pressure and elevated cholesterol to reduce the risk of cardiovascular diseases. This study will test the simultaneous use of a drug to reduce blood pressure and a drug to reduce elevated cholesterol. Both drugs are registered and are effective. The drug for treatment of high blood pressure is telmisartan Micardis). The drug for treatment of elevated cholesterol is simvastatin (Zocor). Since hypertension and hypercholesterolemia frequently occur together, the purpose of this study is to investigate whether both drugs can be used simultaneously. A low dose and a high dose of these drugs will be used. It will be investigated whether each of the drugs is still as effective when given together, at the same time of day, with the other drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent
- •Age 18 years or older
- •Hypertension as defined by a mean seated cuff DBP of >=95 - 109 mmHg
- •Hypercholesterolemia as defined by a fasting LDL-C level at visit 2 according to
- •CV risk shown in table below:
- •CV Risk Group:
- •Group I Hypertension and Hypercholesterolemia only
- •Group II Hypertension and Hypercholesterolemia plus > 1 risk factors
- •Group III Hypertension and Hypercholesterolemia plus CHD and/or diabetes mellitus and/or other athero-sclerotic disease
- •Fasting LDL-C group I and II: 100-250 mg/dL (2.6-6.5 mmol/L)
- •Fasting LDL-C group III: 100-160 mg/dL (2.6-4.1 mmol/L)
- •Risk factors: >= 45 yrs if male, >= 55 years if female, family history of CHD, current smoker, HDL-C < 40 mg/dL
排除标准
- •pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control
- •inability to stop current antihypertensive and/or cholesterol-lowering therapies
- •contraindication to a washout/placebo treatment
- •clinically relevant cardiac arrhythmias
- •hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve
- •mean sitting SBP >=180 mmHg or mean sitting DBP >=110 mmHg at two consecutive visits
- •known or suspected secondary hypertension
- •known or suspected secondary hyperlipidemia of any etiology
- •diabetes that has not been stable and controlled for the previous three months
- •severe renal dysfunction
- •bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or one kidney
- •biliary obstructive disorders, hepatic insufficiency, including past or current liver disease
- •clinically relevant hypokalaemia or hyperkalaemia
- •uncorrected volume depletion
- •uncorrected sodium depletion
- •any history of myopathy or rhabdomyolysis during the past treatment with HMG Co-A reductase inhibitors
- •concurrent use of large quantities of grapefruit juice
- •known hypersensitivity or intolerance to HMG Co-A reductase inhibitors and/or angiotensin receptor blockers, hereditary fructose intolerance
- •planned significant diet and/or lifestyle (including exercise) changes during the treatment phase of the trial
- •history of drug or alcohol dependency
- •any investigational drug therapy within one month of providing informed consent
- •any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medications
结局指标
主要结局
Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean diastolic blood pressure (DBP)
时间窗: 8 weeks
Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean low density lipoprotein (LDL)
时间窗: 8 weeks
次要结局
- Change in Total cholesterol(after 8 weeks)
- Change in triglycerides(after 8 weeks)
- Change in free fatty acids(after 8 weeks)
- Changes in Trough-to-peak ratios of SBP and DBP, taken from ABPM(after 8 weeks)
- Response rate to blood pressure treatment(after 8 weeks)
- Response rate to lipid lowering treatment(after 8 weeks)
- Change in Apolipoprotein B(after 8 weeks)
- Change in Adiponectin(after 8 weeks)
- Change in the 24-hour ABPM (Ambulatory Blood Pressure Monitoring) measured mean SBP(after 8 weeks)
- Changes in Seated morning DBP and SBP(after 8 weeks)
- Change in HDL-cholesterol(after 8 weeks)
- Changes in microalbuminuria(after 8 weeks)
- Changes in clinical laboratory parameter(up to 15 weeks)
- Change in HOMA-index(after 8 weeks)
- Change in haemoglobin A1C(after 8 weeks)
- Changes in high sensitive c-reactive protein(after 8 weeks)
- Adverse events(up to 15 weeks)
- Assessment of pulse rate(up to 15 weeks)